Scientists have identified a protein that appears to put the brakes on the chronic inflammation linked to aging. Older mice ...

This company says its pulsed plasma machine will deliver electricity to the grid by 2029. Some physicists warn that its ...

Infex Therapeutics is pushing ahead with the development of a non-cystic fibrosis bronchiectasis (NCFB) drug candidate after ...

Why do you crash at 2 PM every day? We answered your biggest questions about the dreaded afternoon slump happens and how to beat it.

Coffee may give your blood pressure a temporary jolt, but that doesn’t mean it’s secretly wrecking your heart. Researchers ...

Solar panels stop working when the sky goes dark. That simple fact has pushed energy researchers into a stubborn problem: how ...

Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide ...

A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...

Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease ...

They suggest, instead, a replicable set of conditions under which the freebie works, equally precise conditions under which ...

Aulos Bioscience, a clinical-stage immuno-oncology company developing an immune-activating antibody therapeutic designed by leveraging an AI platform, today announced positive Phase 2 data from its ...